Related Experiment Videos
Placebo control groups in randomized treatment trials: a statistician's perspective.
1Department of Veterans Affairs Cooperative Studies Program, VA Palo Alto Health Care System, Menlo Park, California 94025, USA.
Biological Psychiatry
|April 22, 2000
Summary
Most psychopharmacology trials use placebo controls, raising ethical concerns. This review highlights statistical issues with placebo use, emphasizing the need for careful consideration of trial design and informed consent in psychiatric research.
Area of Science:
- Psychopharmacology
- Clinical Trial Design
- Medical Ethics
Background:
- Psychopharmacology trials often use placebo controls, even when standard treatments exist.
- This practice is debated due to statistical and ethical considerations.
Purpose of the Study:
- To review statistical issues influencing the ethics of using placebo controls in psychopharmacology.
- To examine the implications for trial methodology and informed consent.
Main Methods:
- Review of statistical challenges in placebo-controlled trials.
- Analysis of assumptions regarding delayed standard treatment.
- Examination of methodological weaknesses in trial designs.
Main Results:
- Placebo-controlled trials may have reduced inferential power due to methodological weaknesses like nonrandom truncation.
- Assumptions about the safety of delayed standard treatment are difficult to test empirically.
- Informed consent processes are significantly burdened by these statistical subtleties.
Conclusions:
- Alternative trial designs exist but are underexplored due to regulatory standards.
- Researchers should consider trial goals beyond introducing treatments superior only to placebo.
- Ethical use of placebo controls requires careful statistical and methodological evaluation.